2022 Revenues ($USD) : $26,323,000,000.00
2022 R&D spend : $4,434,000,000.00
2022 Number of Employees : 25,200
Fiscal Year End : 12/31/22
Leader : CEO Robert Bradway

Founded in 1980, Amgen remains a prominent biopharma company focused on developing therapies in a variety of disease areas, including oncology, cardiovascular, inflammation and neuroscience. In 2022, the company reported a 1% revenue growth, totaling $26.3 billion. Over the years, Amgen has obtained significant FDA approvals, such as the migraine therapy Aimovig (erenumab) and the cholesterol drug Repatha (evolucumab). In June 2022, the company announced that it won approval for Riabni (rituximab-arrx), a biosimilar to Rituxan, indicated for certain patients with moderate to severely active rheumatoid arthritis (RA). —BB